T. Rueckle

ASK1 promotes the contact hypersensitivity response through IL-17 production

M. Camps, H. Ji, H. Ichijo, 2014, Scientific Reports.

A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.

David M. Shackleford, R. Price, P. Rathod, 2016, ACS infectious diseases.

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Farah El Mazouni, T. Laird, P. Rathod, 2015, Science Translational Medicine.

Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs

J. Kublin, S. Kappe, B. Greenhouse, 2017, Malaria Journal.

Medicinal Chemistry Case History: Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate

P. Rathod, M. Phillips, S. Charman, 2017 .

A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation

J. Kublin, S. Kappe, Y. Fong, 2018, The Journal of infectious diseases.

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Farah El Mazouni, T. Laird, P. Rathod, 2015, Science Translational Medicine.